ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

Eur UrolJul 8, 2026 (epub)
Clinical ResearchUrologyOncology (Medical)

Daria Chernysheva, Francesco Di Bello, Giulio Avesani et al.

✦ AI-curated · Sources linked

In 30 seconds

The ProBIOPSY project aimed to standardize prostate biopsy procedures through an international consensus involving 34 experts. A systematic review and a modified Delphi process led to consensus on 29 of 36 stems (81%). The consensus supports both biparametric and multiparametric MRI in the diagnostic pathway, emphasizing the need for tailored biopsy strategies for treatment planning.

Key findings

  • Consensus was achieved for 29 of 36 stems (81%) regarding prostate biopsy standards.
  • Both biparametric and multiparametric MRI were endorsed for the diagnostic pathway.
  • A targeted ± perilesional biopsy scheme is sufficient for most local treatment planning.
  • Contralateral sampling remains necessary for specific indications, particularly focal therapy.

Why it matters

Standardizing prostate biopsy procedures can enhance diagnostic accuracy and treatment planning, ultimately improving patient outcomes. Clinicians can benefit from a clearer framework for biopsy strategies tailored to individual patient needs.

What to keep in mind

Limitations include imbalances in specialty representation and heterogeneity in expertise across topics.

Source

PubMed · PMID 42420069

Published in Eur Urol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.